ERBB2 and chronic myelogenous leukemia, BCR-ABL1 positive: This compound improved the overall survival rates of CML patients to 90% over 5 years and 88% over 8 years.16 Another example includes the effectiveness of drugs like trastuzumab, lapatinib, pertuzumab, or ado-trastuzumab emtansine against human epidermal growth factor receptor 2 (HER2)-positive breast cancer.